Immunicum AB (DE:1YG0)
FRANKFURT:1YG0
1YG0 Stock Chart & Stats
€0.49
-€0.01(-1.68%)
At close: 4:00 PM EST
€0.49
-€0.01(-1.68%)
Day’s Range― - ―
52-Week Range€0.35 - €0.87
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€24.01M
Enterprise Value€185.35M
Total Cash (Recent Filing)€64.66M
Total Debt (Recent Filing)€33.28M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding62,584,580
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)€460.44K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a meaningful equity base provide structural financial flexibility. Over a multi‑month horizon this reduces near‑term bankruptcy risk and improves ability to pursue partnerships or raise capital on less dilutive terms, supporting continuity of R&D programs.
Focused Immune‑oncology R&DA concentrated focus on cell‑based immune‑oncology builds specialized technical know‑how and IP that can be monetized via partnerships or licensing. This durable scientific positioning creates high barriers to entry and long‑term strategic optionality if clinical data advance.
Improving Cash Burn TrendReduced negative free cash flow in recent years signals better operational discipline and modest extension of runway. If sustained, this structural improvement lowers near‑term funding pressure and gives management more time to achieve value‑creating clinical or partnering milestones.
Bears Say
Zero Recent RevenueNo recurring product revenue undermines durable self‑funding ability and means the company cannot rely on sales to cover R&D or G&A. Over months this leaves operations exposed to funding cycles and makes long‑term execution contingent on external capital or successful asset monetization.
Persistent Operating LossesSustained operating and net losses erode equity and limit internal reinvestment capacity. Persisting losses increase the likelihood of future dilution or asset dispositions, constrain strategic options, and heighten risk that the firm cannot sustain multi‑year clinical programs without new funding.
Dependence On External FinancingReliance on equity raises and milestone‑based partnerships is a durable structural weakness: access to capital and partner appetite drive the company’s ability to progress trials. This dependence risks dilution, timing uncertainty, and potential project reprioritization if markets or partner interest weaken.
1YG0 FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is €24.01M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 30 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Feb 11, 2026. The company reported -€0.068 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.068.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 62,584,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -€0.068 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.982%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in DE:1YG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunicum AB
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Technical Analysis
Magle Chemoswed Holding AB
―
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Cantargia AB
―